Clinical trials: Population at Risk
Meningococcal Disease, Meningococcal Meningitis
A Phase 3b Study to Assess the Safety of Novartis Meningococcal B Recombinant Vaccine When Administered in Healthy At-risk Adults
The proposed study will evaluate the safety of the rMenB+OMV NZ in an adult population potentially at risk for meningococcal disease (e.g. lab workers).
- Trial name
- NCT01478347
- Testing
- Recombinant meningococcal B + OMV NZ
- Where
- Italy
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Meningococcal Disease
Safety and Immunogenicity of Novartis Meningococcal B Vaccine When Administered to Immunocompromised Children and Adolescents Compared to Healthy Subjects.
The study aims at evaluating the safety and immunogenicity of rMenB+OMV NZ when administered to subjects from 2 to 17 years of age with increased risk of meningococcal disease because either of primary or secondary complement…
- Trial name
- NCT02141516
- Testing
- rMenB+OMV
- Where
- 20 sites in Italy, Poland and 3 more
- Volunteers
- 239 people, healthy volunteers welcome
- Sponsor
- Novartis
Physical Disability
On the Move: Optimizing Participation in Group Exercise
Community-dwelling older adults fear loss of independence and nursing home placement more than death. Walking difficulty often leads to loss of independence.
- Trial name
- OTM-PCORI (NCT01986647)
- Testing
- On the Move exercise - exercise leader, Standard program - exercise leader, On the Move exercise - staff activity personnel
- Where
- United States
- Volunteers
- 424 people, healthy volunteers welcome
- Sponsor
- University of Pittsburgh
Alzheimers Disease
A Study of CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease
The purpose of this study is to determine the effects of CNP520 on cognition, global clinical status, and underlying AD pathology, as well as the safety of CNP520, in people at risk for the onset of clinical symptoms of AD based…
- Trial name
- GS2 (NCT03131453)
- Testing
- CNP520 50mg, CNP520 15mg
- Where
- 194 sites in United States, Argentina and 23 more
- Volunteers
- 1,145 people, healthy volunteers welcome
- Sponsor
- Novartis Pharmaceuticals
Glaucoma, Diabetic Retinopathy
Providing Financial Incentives to Improve Adherence to Referral Eye Care Visits
Glaucoma is a blinding eye disease increasingly common in older adults, particularly in African Americans, and often diagnosed late in the disease course.
- Conditions
- Glaucoma, Diabetic Retinopathy, Refractive Errors, Cataract
- Trial name
- AL-SIGHT (NCT04328207)
- Testing
- No Financial Incentive, Financial Incentive
- Where
- United States
- Volunteers
- 900 people, healthy volunteers welcome
- Sponsor
- University of Alabama at Birmingham
Lung Cancer
The INSPIRE-Lung Study
LungTalk and leveraging Facebook-targeted Advertisement (FBTA) addresses the call to develop and test multi-level, cancer communication interventions using innovative methods and designs.
- Trial name
- NCT05824273
- Testing
- LungTalk, Non-tailored intervention - Standard of practice
- Where
- United States
- Volunteers
- 512 people, healthy volunteers welcome
- Sponsor
- Hackensack Meridian Health
Barrett Esophagus
Clinical Utility of a Non Endoscopic Device EsoCheck and Biomarker EsoGuard as Alternative to Endoscopy for Screening for Barrett's Esophagus in At Risk Population
This will be a prospective randomized, controlled, virtual, patient study to measure the impact of EsoCheck/EsoGuard on health care provider's decision for upper endoscopy referral.
- Trial name
- ASBE (NCT05778851)
- Testing
- EsoGuard result
- Where
- United States
- Volunteers
- 97 people, healthy volunteers welcome
- Sponsor
- Lucid Diagnostics, Inc.
Pneumococcal Disease
A Phase III Clinical Trial to Study the Safety and Immunogenicity of Pneumovax™ 23 (V110) in Participants From the Russian Population (V110-018)
The purpose of this study is to determine if Pneumovax™ 23 (V110) is safe and immunogenic in participants from the Russian population who are 50 years of age and older or 2 to 49 years of age and at increased risk for…
- Trial name
- NCT01734239
- Testing
- Pneumovax™ 23
- Volunteers
- 102 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
HIV Infections, Sexually Transmitted Diseases
A Peer-Oriented HIV Prevention Outreach Program for Individuals at High Risk for HIV and Other STIs
This study will determine the effectiveness of a peer outreach intervention in preventing HIV infection in adults at high risk for contracting HIV and other sexually transmitted diseases (STDs).
- Trial name
- NCT00183456
- Testing
- Peer-oriented intervention, Group cognitive behavioral therapy (CBT)
- Where
- United States
- Volunteers
- 746 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins Bloomberg School of Public Health
Platelet Dysfunction Due to Aspirin
Genotypic and Phenotypic Correlates of Resistance to Aspirin
The study seeks to identify genomic markers associated with aspirin resistance.
- Trial name
- ARSENAL (NCT01361620)
- Testing
- aspirin
- Where
- United States
- Volunteers
- 190 people, healthy volunteers welcome
- Sponsor
- George Washington University
Asymptomatic Amyloid-positive
An Efficacy and Safety Study of Atabecestat in Participants Who Are Asymptomatic at Risk for Developing Alzheimer's Dementia
The purpose of this study is to evaluate whether treatment with atabecestat slows cognitive decline compared with placebo treatment, as measured by a composite cognitive measure, the Preclinical Alzheimer Cognitive Composite…
- Trial name
- EARLY (NCT02569398)
- Testing
- Atabecestat, 5 mg, Atabecestat, 25 mg
- Where
- 128 sites in United States, Australia and 11 more
- Volunteers
- 557 people, healthy volunteers welcome
- Sponsor
- Janssen Research & Development, LLC
COVID-19
Special Investigation of COMIRNATY in the Population With Underlying Diseases
Post-marketing study, Cohort study of COMIRNATY vaccines. To collect information on adverse events and COVID-19 observed after vaccination with COMIRNATY and to assess safety in patients with underlying disease considered to be…
- Trial name
- NCT04880447
- Testing
- BNT162b2
- Where
- Japan
- Volunteers
- 1,075 people, healthy volunteers welcome
- Sponsor
- Pfizer
Cardiovascular Diseases
Cardiovascular Disease Population Risk Tool
The purpose of this study is to develop, evaluate, and apply a predictive algorithm for assessing CVD risk in the community setting: the Cardiovascular Disease Population Risk Tool (CVDPoRT).
- Trial name
- CVDPoRT (NCT02267447)
- Volunteers
- 104,219 people, healthy volunteers welcome
- Sponsor
- Ottawa Hospital Research Institute
HIV, Hepatitis B
Pilot Study Evaluating the Use of Simultaneous HBV, HCV, and HIV Rapid Tests
This is a pilot, monocentric, prospective, randomized control trial looking at the use of rapid tests as a part of normal care. The investigators will be testing for hepatitis B virus (HBV), hepatitis C virus (HCV), and human…
- Conditions
- HIV, Hepatitis B, Hepatitis C, Carcinoma, Hepatocellular
- Trial name
- OPTISCREEN-III (NCT01790633)
- Testing
- ELISA, Rapid Test
- Where
- France
- Volunteers
- 327 people, healthy volunteers welcome
- Sponsor
- Institut de Médecine et d'Epidémiologie Appliquée - Fondation Internationale Léon M'Ba